Drdevaraju S

Dr.devaraju S. currently serves as Senior Director at Eli Lilly and Company, where he provides strategic leadership and oversight for global safety surveillance activities. His role encompasses the end-to-end management of routine signal detection in Individual Case Safety Reports (ICSRs), clinical trial data, and scientific literature, ensuring robust pharmacovigilance practices across the organization. Dr.devaraju’s expertise in medical review of clinical trial data and case analysis is instrumental in identifying potential safety signals early, facilitating timely regulatory actions and risk mitigation strategies. He plays a pivotal role in managing labeling changes for clinical overview reports, ensuring that safety information remains current and compliant with regulatory standards.

In addition to his core responsibilities, Dr.devaraju leads the development of comprehensive safety documentation, including Periodic Benefit-Risk Evaluation Reports (PBRERs), Periodic Adverse Drug Experience Reports (PADERS), and benefit-risk assessments for mature products. His deep understanding of MedDRA coding, epidemiology, and GCP/ICH-GCP guidelines enhances the accuracy and reliability of safety data interpretation. As a key member of the global medical team, he provides medical leadership in early-phase clinical trials, contributing to safety surveillance programs and risk management planning. His expertise extends to PRAC assessments and signal detection activities, supporting Eli Lilly’s commitment to patient safety and regulatory compliance.

Dr.devaraju’s strategic insights and cross-functional collaboration ensure that safety considerations are integrated into all aspects of product development and lifecycle management. His leadership in pharmacovigilance and medical review underscores his commitment to advancing innovative therapies while maintaining the highest standards of drug safety and efficacy in the pharmaceutical industry.